RECURRENT PANCREATIC CARCINOMA
Clinical trials for RECURRENT PANCREATIC CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PANCREATIC CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PANCREATIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat GI cancers
Disease control CompletedThis early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a PARP inhibitor boost chemo for pancreatic cancer?
Disease control CompletedThis phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. 123 patients whose cancer had returned after initial treatment were randomly assigned to get FOLFIRI alone or FOLFIRI plus ve…
Matched conditions: RECURRENT PANCREATIC CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC